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complexALys3, the primer for reverse transcriptase (RT) in HIV-1, is selectively packaged
into the virus due to a speciﬁc interaction between Gag and lysyl-tRNA synthetase (LysRS). However, while
Gag alone will incorporate LysRS, tRNALys3 packaging also requires the presence of RT thumb domain
sequences in GagPol. The formation of a tRNALys3 packaging/annealing complex involves an interaction
between Gag/GagPol/viral RNA and LysRS/tRNALys, and herein, we have investigated whether the transfer of
tRNALys3 from LysRS to RT sequences in Pol by a currently unknownmechanism is facilitated by an interaction
between LysRS and Pol. We demonstrate that, in addition to its interaction with Gag, LysRS also interacts with
sequences within the connection/RNaseH domains in RT. However, cytoplasmic Gag/Pol interactions,
detected by either coimmunoprecipitation or incorporation of Pol into Gag viral-like particles, were found to
be insensitive to the overexpression or underexpression of LysRS, indicating that a Gag/LysRS/RT interaction
is not essential for Gag/Pol interactions. Based on this and previous work, including the observation that the
RT connection domain is not required for tRNALys3 packaging, but is required for tRNALys3 annealing, a model
is proposed for a tRNALys3 packaging/annealing complex in which the interaction of Gag with Pol sequences
during early viral assembly facilitates the retention in budding viruses of both tRNALys3 and early Pol
processing intermediates, with tRNALys3 annealing to viral RNA further facilitated by the LysRS/RT interaction.
© 2008 Elsevier Inc. All rights reserved.Introduction
In lentiviruses, including HIV-1, tRNALys3 serves as the primer tRNA
for the reverse transcriptase (RT)-catalyzed synthesis of minus strand
strong stop DNA (Leis et al., 1993; Mak and Kleiman, 1997). tRNALys3
and the other major tRNALys isoacceptors, tRNALys1 and tRNALys2
(referred to collectively as tRNALys1,2, since these two isoacceptors
differ by only one base pair in the anticodon stem) are selectively
packaged into the virus (Mak et al., 1994). While the function of
tRNALys1,2 in HIV-1 is not known, the selective packaging of primer
tRNALys3 is required for optimizing both the annealing of tRNALys3 to
viral RNA and the infectivity of the HIV-1 population (Gabor et al.,
2002). The major structural protein in HIV-1, Gag, is capable, with the
help of genomic or cellular RNA, of forming extracellular Gag viral-like
particles (VLPs) (Campbell and Vogt, 1995; Gross et al., 1997; Khorchid
et al., 2002; Muriaux et al., 2001), but these Gag VLPs do notical Research, Jewish General
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l rights reserved.selectively incorporate tRNALys unless GagPol is also present (Mak
et al., 1994).
The interaction between GagPol and tRNALys3 involves the thumb
domain (TH) sequences in RT (Khorchid et al., 2000), andwhile GagPol
plays the role of stabilizing the tRNALys in the Gag/GagPol/viral RNA
complex, Gag plays the important role of selecting tRNALys isoaccep-
tors for incorporation into HIV-1. It does so by speciﬁcally binding the
tRNALys binding protein, lysyl-tRNA synthetase (LysRS), and this
protein is incorporated into both HIV-1 and Gag VLPs (Cen et al.,
2001). The interaction of Gag with LysRS is very speciﬁc, i.e., of 12
aminoacyl tRNA synthetases (aaRSs) and 3 related proteins tested,
only LysRS is packaged (Halwani et al., 2004). Domains critical for the
Gag/LysRS interaction have been mapped to include the dimerization
domains of both LysRS and capsid (CA) (Javanbakht et al., 2003).
Recent work using ﬂuorescent anisotropy to study the in vitro
interaction of LysRS with either Gag, CA, or the C-terminal domain
of CA, has more ﬁnely mapped the interacting sites to helix 7 of LysRS
and helix 4 of the C-terminal domain of CA (Kovaleski et al., 2006,
2007). Viral LysRS does not appear to originate from any of its
identiﬁed steady-state cellular compartments, which include a
cytoplasmic high molecular weight aaRS complex, nuclei, mitochon-
dria, and cell membrane. Instead, newly-synthesized LysRS appears to
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al., 2003; Halwani et al., 2004). The packaging of tRNALys isoacceptors
requires interaction with LysRS (Javanbakht et al., 2002), but not
aminoacylation of the tRNA (Cen et al., 2004a). Based upon these
ﬁndings, we have postulated a model for the formation of a tRNALys
packaging/annealing complex, in which a Gag/GagPol/viral RNA
complex interacts with a tRNALys/LysRS complex, with Gag interacting
with both GagPol and LysRS, and GagPol also interacting with tRNALys
through the TH domain in RT (see Fig. 5A).
The in vivo interaction of Gag with GagPol has been well
documented (Park and Morrow, 1992), (Smith et al., 1990, 1993;
Srinivasakumaret al.,1995), and it is believed thatGagPol is carried into
the assembling Gag particle by interaction of Gag sequences in GagPol
with those in Gag. Based on the interactions occurring between Gag
molecules, the interaction between Gag and Gag sequences in GagPol
may only involve the C-terminal domain of CA and SP1 sequences.
Thus, cryoelectron microscopy has indicated that in immature virions,
Gag is radially distributed in the virion, with the N-terminal sequences
within thematrix (MA) domain associated withmembrane, and the C-
terminal sequences coding for SP2-nucleocapsid (NC)-p6 nearest the
center of the virion (Fuller et al., 1997; Wilk et al., 2001). Images of
immature virions have suggested that Gag molecules may be arranged
in interacting hexagonal bundles, with a Gagmolecule at each vertexofFig. 1. Interaction of Pol sequences with LysRS. 293T cells were transfected with plasmids c
fragments with endogenous LysRS was determined by immunoprecipitation of cell lysates w
with anti-V5. (A) Cartoon of Pol and Pol fragments expressed in 293T cells. (B) Cellular expres
panel) or anti-β-actin (lower panel). (C) Interaction of LysRS with Pol fragments. Cell lysates w
were probed with anti-V5.the hexagon (Briggs et al., 2006; Mayo et al., 2003; Nermut et al., 1998;
Wright et al., 2007), which is supported by work studying the in vitro
assembly of Gag (Huseby et al., 2005). The hexagonal order, however,
appears to beprimarily at the level of CA andSP1, and is not foundat the
levels N- or C-terminal to these regions (Briggs et al., 2006;Mayo et al.,
2003; Nermut et al.,1998;Wright et al., 2007), suggesting that Gag/Gag
interactions may occur primarily at the CA/SP1 region.
Interactions between individually expressed HIV-1 Pol and Gag
molecules have also been reported, reminiscent of the intermolecular
interaction between Pol and Gag in human foamy viruses, which are
expressed from separate mRNAs (Stenbak and Linial, 2004). Expres-
sion of HIV-1 Pol and Gag from separate plasmids in 293T cells not
only results in the incorporation of Pol into Gag VLPs, but Pol can
replace GagPol in facilitating the selective incorporation of tRNALys
into the Gag VLPs (Cen et al., 2004b). A recent report also indicates
that RT sequences alone can be incorporated into Gag VLPs, with
apparent interactions occurring between matrix and p6 sequences in
Gag and the TH domain in RT (Liao et al., 2007).
Because the formation of the tRNALys3 packaging/annealing
complex appears to require a transfer of tRNALys3 by an unknown
mechanism from LysRS to RT sequences in Pol, we have investigated
whether there is a direct interaction between LysRS and Pol, and in
this work, we demonstrate the existence of such an interaction.oding for V5-tagged full-length Pol or truncated Pol fragments. Interaction of these Pol
ith anti-LysRS, followed by probing western blots of the anti-LysRS immunoprecipitates
sion of Pol fragments. Western blots of cellular lysates were probed with anti-V5 (upper
ere immunoprecipitated with anti-LysRS, and western blots of the immunoprecipitates
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Interaction of HIV-1 Pol with cellular LysRS
We ﬁrst determined by coimmunoprecipitation if Pol or Pol
fragments expressed in the cell would interact with endogenous
LysRS. 293T cells were transfected with a plasmid coding for HIV-1 Pol
or fragments of Pol, all C-terminally tagged with V5. 48 h post-
transfection, endogenous LysRS was immunoprecipitated from cell
lysate with anti-LysRS. Western blots of the immunoprecipitate were
then probed with anti-V5 to examine the ability of endogenous LysRS
to interact with Pol or Pol fragments, and these results are shown in
Fig. 1. Panel A shows a cartoon of the Pol and Pol fragments tested, and
displays the coding domains for protease (PR), RT, and integrase (IN),
and the position of the various structural domains of RT, that include
the ﬁnger–palm domain (FP), TH, connection domain (CD), and the
RNaseH domain (RN); Panel B shows the cellular expression of these
fragments, while panel C shows the ability of the fragments to be
coimmunoprecipitated with anti-LysRS. In the left blot of panel C, it
can be seen that Pol binds to LysRS, but weakly, and removal of p6⁎
and PR does not alter this weak binding. However, removal of N-
terminal sequences in Pol through FP result in a signiﬁcant increase in
bindingwhich is retainedwhenTH is also removed. In themiddle blot,
it can be seen that the C-terminal deletion of IN in Pol also results in an
increased binding to LysRS compared to full-length Pol. The right blot
in panel C shows that the N-TH fragment binds much more poorly to
LysRS than the N-RN fragment, but because cellular expression of N-
CD is poor, the results for this fragment are non-informative.
The data in Fig. 1 indicate that sequences in Pol binding to LysRS
are found within CD/RN of RT. They also demonstrate that removal of
either N-terminal sequences through FP, or the C-terminal IN results
in signiﬁcant increases in binding to LysRS. The much weaker binding
of LysRS to Pol, PR-C, and FP-C may reﬂect a conformation that masks
the LysRS binding sequences within Pol, but an alternative explana-
tion is that this much weaker binding represents non-speciﬁc
background binding, which would also account for the similar weak
binding exhibited by the N-TH fragment. In the natural state, where
Pol is covalently attached in cis to Gag, the LysRS binding sites in Pol
(CD/RN) may be more exposed.
Interaction of HIV-1 RT with cellular LysRS
Finer mapping of the LysRS binding site in Pol RT sequences was
done by measuring the cytoplasmic interaction of wild-type and
mutant forms of RT with endogenous LysRS. 293T cells were
transfected with a plasmid coding for V5-tagged RT, and the ability
of RT to coimmunoprecipitate with cellular LysRS was examined by
immunoprecipitating cell lysatewith anti-LysRS, and probingWesternFig. 2. Interaction of RT sequences with LysRS. 293T cells were transfected with
plasmids coding for V5-tagged full-length RT or truncated RT fragments. Interaction of
these RT fragments with endogenous LysRS was determined by immunoprecipitation
of cell lysates with anti-LysRS, followed by probing western blots of the anti-LysRS
immunoprecipitates with anti-V5. (A) Speciﬁcity of RT and LysRS interaction. 293T
cells were transfected with a plasmid coding for full-length RT. Western blots of cell
lysates were probed with anti-V5 (left upper panel), anti-GAPDH (left middle panel)
or anti-β-actin (left lower panel). Cell lysates were then immunoprecipitated with
anti-LysRS, and western blots of the immunoprecipitates were probed with anti-V5
(right upper panel), anti-GAPDH (glyceraldehyde-3-phosphate dehydrogenase (right
middle panel)) or anti-β-actin (right lower panel). (B) RNA-independence of the RT/
LysRS interaction. Lysates of cells expressing RT and β-actin (western blots shown in
the upper two panels) were immunoprecipitated with anti-LysRS. The immunopre-
cipitate was, or was not, treated with RNase A and T1 RNase, and the bottom panel
shows a western blot of untreated or treated immunoprecipitate probed with anti-V5.
(C) Cartoon of RT and RT fragments expressed in 293T cells. (D) Cellular expression of
RT fragments. Western blots of cellular lysates were probed with anti-V5 (upper
panel) or anti-β-actin (lower panel). (E) Interaction of LysRS with RT fragments. Cell
lysates were immunoprecipitated with anti-LysRS, and western blots of the
immunoprecipitates were probed with anti-V5.blots of the immunoprecipitate with anti-V5. To test for the speciﬁcity
of the interaction, the presence in the immunoprecipitate of two
common cellular proteins, GAPDH and β-actin, were also probed for
with antibodies to these proteins. The results, shown in Fig. 2A,
indicate an interaction between RT and LysRS, but no interaction
between LysRS and either GAPDH or β-actin. In panel B, we tested if
RNA plays a role in facilitating the LysRS/RT interaction by treating the
anti-LysRS immunoprecipitate after bead washing with RNases A and
T1. The results surprisingly show that removal of RNA results in a
stronger interaction between LysRS and RT, suggesting that RNA in the
immunoprecipitate may be partially blocking the interaction between
anti-V5 and the V5 epitope. Similar results are seen if cell lysate is
treated with RNase prior to immunoprecipitation (data not shown),
112 J. Saadatmand et al. / Virology 380 (2008) 109–117and the results indicate that RNA does not play a role in facilitating the
LysRS/RT interaction.
We next mapped the sequences in RT that are required for
interacting with LysRS. 293T cells were transfected with plasmidsFig. 3. Pol or RT interaction with Gag. (A–C.) 293T cells were cotransfected with a plasmid co
Coding regions of Gag and GagΔp6. (B) Left panel: Cellular expression of Gag, GagΔp6, Pol
(upper panel), anti-V5 (middle panel), or anti-β-actin (lower panel). Right panel: Cell lysate
were probed with anti-CA. (C) Left panel: Cellular expression of RT, Gag, and β-actin, using w
(middle panel) or anti-β-actin (lower panel). Right panel: Cell lysates were immunoprecipita
RT. (D) 293T cells were cotransfected with a plasmid coding for HIV-1 RT and either GagFS−
panel: Cellular expression of RT and β-actin, using western blots of cellular lysates probed, re
Western blots of lysates of extracellular Gag VLPs, probed with anti-V5 (right upper panel) or
lower panel).coding for RT or RT fragments, V5-tagged at the C-terminus. Cell
lysates were immunoprecipitated with anti-LysRS, and Western blots
were probed with anti-V5 to determine which RT fragments
immunoprecipitated with LysRS. The results are shown in Fig. 2C–E.ding for Gag or GagΔp6, and a plasmid coding for either V5-tagged Pol (B) or RT (C). (A)
, and β-actin, using western blots of cellular lysates probed, respectively, with anti-CA
s were immunoprecipitated with anti-V5, and western blots of the immunoprecipitates
estern blots of cellular lysates probed, respectively, with anti-RT (upper panel), anti-CA
ted with anti-CA, and western blots of the immunoprecipitates were probed with anti-
(coding for all HIV-1 proteins except GagPol), or a plasmid coding for RSV Gag.P−. Left
spectively, with anti-V5 (left upper panel) or anti-β-actin (left lower panel). Right panel:
anti-CA (right middle panel). Western blots of RSV VLPs, probed with RSV anti-CA (right
Fig. 4. Effect of alterations in LysRS expression upon Gag interaction with Pol or RT. (A)
293Tcells were cotransfectedwith plasmids coding for Gag and RT. Some cells were also
transfected with a third plasmid, either empty (pcDNA), or coding for LysRS (pLysRS),
while other cells were transfected with siRNA to either luciferase (siCon) or to LysRS
(siLysRS), 8 h prior to transfectionwith DNA plasmids for Gag and RT. In panel A, left, cell
expression of proteins 48 h post-transfection is shown by probing western blots of cell
lysates with either anti-LysRS (left upper panel), anti- β-actin (left second panel), anti-
RT (left third panel), and anti-CA (left lower panel). The cell lysates were
immunoprecipitated with anti-CA, and western blots of the immunoprecipitate (right
side, panel A were probed with either anti-RT (right upper panel) or anti-CA (right
lower panel). (B) Eight hours after transfecting 293T cells with siCon or siLysRS, the cells
were cotransfected with GagFS− and a plasmid coding for Pol. In panel B, left, cell
expression of proteins 48 h post-transfection is shown by probing western blots of cell
lysates with either anti-LysRS (left upper panel), anti-β-actin (left second panel), anti-
V5 (left third panel), and anti-CA (left lower panel). Right panel: Western blots of lysates
of extracellular Gag VLPs, probed with anti-V5 (right upper panel) or anti-CA (right
lower panel).
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cellular expression, and Fig. 2E shows the ability of the RT fragments
to be coimmunoprecipitated with anti-LysRS. As shown in the left gel
in panel E, there is an increasing ability of LysRS to bind to RT
fragments in the order RTbFP-CDbTH-RN, while the much weaker
binding of FP-TH is suggestive of non-speciﬁc background binding. It
can also be seen in panel D that because the CD-RN and TH-CD
fragments are expressed very poorly, the binding results for these
fragments are non-informative. The results, therefore, from Figs. 1 and
2, indicate a binding site for LysRS mapping to the RT CD/RN domains
in Pol. While the interaction between Gag and LysRS has been
demonstrated both in vivo (Javanbakht et al., 2003) and in vitro
(Kovaleski et al., 2006), attempts to demonstrate an in vitro interaction
between either puriﬁed RT or puriﬁed TH-RN and puriﬁed LysRS,
using coimmunoprecipitation with anti-LysRS, have thus far failed
(data not shown). Furthermore, the addition of either puriﬁed RT or
TH-RN produced in Escherichia coli to a cell lysate, followed by
immunoprecipitation of endogenous LysRS with anti-LysRS also failed
to show an interactionwith LysRS (data not shown). Thus, we are only
able to show an interaction between LysRS and RT or TH-RN when
both are expressed in the cell (see Fig. 2C). This could indicate a
requirement for unknown cell factors whose compartmentalization is
disrupted in cell lysate, but could also be indicative of differences in
modiﬁcation between E. coli-produced RT fragments (including the
presence of a His-tag used for puriﬁcation) and RT fragments
synthesized in mammalian cells. Also, since the source of viral LysRS
is newly-synthesized LysRS (Guo et al., 2003), a requirement for the
LysRS/RT interaction may also be the use of newly-synthesized RT.
The LysRS/Pol interaction is not required for Gag/Pol interaction
We next investigated whether the LysRS/Pol interaction was
essential for the interaction between Gag and Pol. We have previously
shown that in 293T cells expressing Gag and Pol from separate
plasmids, Pol was incorporated into Gag VLPs, and was itself sufﬁcient
for facilitating the selective packaging of tRNALys (Cen et al., 2004b).
That work also showed that removal of sequences either upstream or
downstream of RT-coding sequences did not reduce incorporation of
the truncated Pol, suggesting that sequences within RT were
responsible for Pol incorporation into Gag VLPs.
In Fig. 3, we provide additional evidence for a cytoplasmic
interaction between Gag and Pol, and one that relies upon the RT
sequences within Pol. Fig. 3A shows the protein coding regions of full-
length Gag and a truncated Gag, GagΔp6, which is missing the C-
terminal p6 sequences. In Fig. 3B, Pol was immunoprecipitated with
anti-V5 from lysates of cells expressing both V5-tagged Pol and either
Gag or GagΔp6, and determined if Gag was detected on western blots
of the immunoprecipitate probed with anti-CA. These results
demonstrate a cytoplasmic interaction between Gag and Pol, and
also show a requirement for Gag p6 sequences for this reaction, a
ﬁnding supported by a previous report demonstrating a requirement
for p6 sequences for the incorporation of Pol into mutant Gag VLPs, in
which the NC and sp2 sequences in Gag had been replaced by a yeast
leucine zipper (Cen et al., 2004b).
In Fig. 3C, the role of RT in the Gag/Pol interaction is demonstrated
by detecting a cytoplasmic interaction between Gag and RT. Gag was
immunoprecipitated with anti-CA from lysates of cells also expressing
RT, and RT was detected in western blots of the immunoprecipitate
with anti-RT. The data in panel D also shows the ability of HIV-1 RT to
be incorporated into HIV-1 Gag VLPs, but not into RSV Gag VLPs. In
order to directly compare the Gag VLPs made from two different
species, HIV-1 Gag was expressed from viral mRNA rather than from
codon-optimized mRNA (as for Fig. 3B, C). 293T cells were cotrans-
fected with a plasmid coding for HIV-1 RT, and a plasmid coding for
either protease-negative RSV Gag or GagFS−, a plasmid coding for all
HIV-1 viral proteins except GagPol (Liang et al., 1997). Western blots ofviral lysates show the incorporation of RT into the viruses. Also shown
is the fact that when 293Tcells are cotransfectedwith plasmids coding
for Rous sarcoma virus (RSV) Gag and HIV-1 RT, RT is not found
incorporated into the RSV Gag VLPs.
In Fig. 4, we determined whether the LysRS/RT interaction was
required for the cytoplasmic interaction between Gag and RT, or for
the incorporation of Pol into Gag VLPs, by examining the effect of
overexpression or underexpression of LysRS upon these parameters.
293T cells were cotransfected with plasmids coding for HIV-1 Gag and
RT. In addition, overexpression of LysRS was achieved by also
transfecting cells with a plasmid coding for LysRS, while under-
expression of LysRS was obtained using siRNA to LysRS. Under the
conditions used, overexpression of LysRS in the cytoplasm results in a
114 J. Saadatmand et al. / Virology 380 (2008) 109–117modest 2 fold increase in the incorporation of LysRS into virions (Cen
et al., 2004a). However, under the conditions used here for siRNA
transfection, we have reported that siRNA to LysRS results in an 80%
decrease in LysRS incorporated into the virions (Guo et al., 2003).
Assuming that the incorporation of LysRS into virions reﬂects its
presence in the tRNALys3 packaging/annealing complex, the results in
Fig. 4A indicate that the alterations in the concentration of LysRS in the
complex resulting from over- or underexpression of LysRS had no
effect upon the interaction of Gag with RT.
In Fig. 4B, we tested the effect of LysRS reduction upon the ability of
Pol to be incorporated into Gag VLPs. 293Tcells were triply transfected
with siRNA to LysRS, and plasmids coding for Gag (GagFS−) and Pol. As
shown in panel B, the reduction of cellular LysRS had no effect upon
the ability of Pol to be incorporated into Gag VLPs. These results
indicate that the interaction between LysRS and Pol sequences, whichFig. 5. The tRNALys3 packaging/annealing complex. (A) Formation of the tRNALys3 packag
complex interacting with a tRNALys3/LysRS complex, with Gag interacting with both GagPol a
described in detail in the text. (B) Proposed relationships existing between components of th
is not known, data in this paper and elsewhere suggests an interaction between Pol and Gag
this work indicates the occurrence of a Gag/LysRS/Pol interaction, it appears that other int
facilitate tRNALys3 packaging and annealing, as well as facilitate retention of partially procemight form a Gag/LysRS/Pol bridge, is not essential for facilitating the
observed Gag/Pol or Gag/RT interactions.
Discussion
While tRNALys is targeted for incorporation into HIV-1 by a select
interaction of HIV-1 Gagwith LysRS, RT sequences within GagPol must
also be present, or LysRS will be packaged without tRNALys (Cen et al.,
2001; Khorchid et al., 2000). A model of how tRNALys3 incorporation
might occur, via the formation of a tRNALys3 packaging/annealing
complex, is shown in Fig. 5A, in which a Gag/GagPol/viral RNA
complex interacts with a tRNALys3/LysRS complex, with Gag binding
speciﬁcally to LysRS, and tRNALys3 binding to TH in the RT sequence in
GagPol. tRNALys3 is uncharged in the virus (Huang et al., 1994), and
must be so if it is to act as a primer for reverse transcriptase. It is noting/annealing complex. The picture shows a previously formed Gag/GagPol/viral RNA
nd LysRS, and GagPol also interacting with tRNALys. The facts supporting this picture are
e tRNALys3 packaging/annealing complex. Although the actual conformation(s) of GagPol
sequences. As described in the text, the nature of this interaction is not clear, and while
eractions also occur. As described in the text, we propose that these relationships will
ssed Pol during early stages of budding.
Table 1
Plasmids used in this study
Plasmida Codon usage Protein expressed
GagFS− Virus Gag
GagΔp6 Codon optimized Gag missing p6
RSV.Gag.P− Virus RSV Gag
Gag Codon optimized Gag
Pol Codon optimized Pol
RT Codon optimized RT
pLysRS Human LysRS
a All viral proteases are inactive.
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the interaction of Gag with LysRS causes both deacylation and the
release of deacylated tRNALys3. The Gag/GagPol ratio in the tRNALys3
packaging/annealing complex is lower than will be found in the
budding virion, based on the following data. When transfected 293T
cells producing HIV-1 are pulsed for 10 minwith 35S-Cys/Met, ∼15% of
newly-synthesized Gag and N95% of newly-synthesized GagPol are
found associated with membrane domains enriched in lipid rafts
(Halwani et al., 2003), which is characteristic of membrane from
which HIV-1 buds (Nguyen and Hildreth, 2000; Ono and Freed, 2001).
The Gag and GagPol molecules at this membrane domain are
presumably in a complex since the movement of GagPol to membrane
requires association with Gag, and this Gag/GagPol association
appears to be driven by the interaction between homologous Gag
sequences within Gag and GagPol (Park and Morrow, 1992; Smith et
al., 1993). Since the ratio of synthesis of Gag/GagPol in cells has been
estimated to be approximately 20:1 (Gendron et al., 2008), the ratio of
newly-synthesized Gag:GagPol at lipid raft domains would be 3:1, i.e.,
much lower than the Gag:GagPol ratio found in immature virions.
With current estimates of the number of Gag molecules in an
immature HIV-1 being ∼4000 (Briggs et al., 2004), the 20:1 synthesis
ratio of Gag:GagPol may suggest approximately 200 molecules of
GagPol per virion, or in the tRNALys3 packaging/annealing complex,
∼600 molecules Gag: 200 molecules GagPol. It was also observed that
during a 30 min chase period, more Gag molecules moved towards
lipid raft-enrichedmembrane (Halwani et al., 2003), implying that the
tRNALys3 packaging/annealing complex may represent a very early
assembly intermediate to which more Gag is later added.
In the model in Fig. 5A, GagPol is shown as a dimer because
dimerization of PR will be required to activate this enzyme for later
Gag and GagPol processing. LysRS is shown as a monomer, since the
dimerization site in LysRS includes the binding site for Gag, and
monomeric LysRS has been shown to interact with Gag in vitro
(Kovaleski et al., 2006).
The data in Fig. 2B indicate that RNA does not play a role in the
LysRS/RT interaction. Similarly, we have found that while RNA
appears to be required for the Gag/GagPol interaction, it is not for a
Gag/Pol interaction (Cen et al., 2004b). Thus, a direct need for RNA
in the Gag/GagPol interaction is implied by the fact that replace-
ment of Gag NC with a yeast leucine zipper motif allows for Gag
particle formation without incorporation of either general RNA or
GagPol. However, these same mutant Gag VLPs do package Pol (Cen
et al., 2004b).
The actual structural conformation of GagPol that would allow for
the Pol sequences to fold backwards and interact with Gag is not
known. While the association of GagPol with Gag is most likely driven
by an interaction between homologous sequences in Gag and GagPol,
we have used the simple cartoon in Fig. 5B to point out how the Pol
interactionwith Gag could prove useful to the virus. The model shows
tRNALys3 bound to TH in RT, which is based both on in vitro studies on
the interaction of puriﬁed HIV-1 RT with tRNALys3 (Arts et al., 1998;
Dufour et al., 1999), and in vivo studies on the effect of C-terminal
deletions in GagPol upon tRNALys3 incorporation into HIV-1 (Cen et al.,
2004; Khorchid et al., 2000). The model also shows the 5′ region of
viral genomic RNA. HIV-1 genomic RNA is packaged into the virus
through interactions between nucleocapsid protein sequences in Gag
and speciﬁc stem/loop structures at the 5′ end of the genomic RNA
(Berkowitz et al., 1996; Geigenmüller and Linial, 1996), and the primer
binding site in viral RNA is located within 100 nucleotides upstream of
these sequences. Thus, the movement of Pol back towards Gag might
facilitate transfer of tRNALys3 from LysRS to RT by an unknown
mechanism, and place tRNALys3 closer to the PBS region in viral RNA
where annealing is to occur. Also, during viral maturation, the ﬁrst
protease cleavage is between NCp7 and SP1 (Pettit et al., 2004), and
may be initiated before viral budding is complete. An interaction
between Pol and Gag could insure that Pol is retained in the partiallyclosed budding particle. The fact that p6 is required for the interaction
of Gag with Pol (Fig. 3B,C) is of interest in this context since it has been
reported that the deletion of p6 from Gag resulted in a lower
concentration of Pol products in protease-positive HIV-1, but no
change in GagPol incorporation in protease-negative viruses (Yu et al.,
1998).
The model in Fig. 5B shows the dual interaction of LysRS with both
the C-terminal domain of Gag capsid and the RT connection domain in
Pol. Determination of the site in LysRS for binding RT has proven to be
technically difﬁcult, and is not yet known. The data in Fig. 4, however,
indicates that the LysRS/RT interaction is not required for the
interaction between Gag and Pol or RT, and other interactions,
involving matrix and p6 sequences in Gag and RT TH sequences in Pol,
have been reported (Liao et al., 2007). Since C-terminal deletions of
GagPol that include the RT connection domain do not inhibit tRNALys3
packaging (Cen et al., 2004), it is clear that the LysRS/RT interaction is
also not involved in facilitating tRNALys3 packaging. On the other hand,
that same report showed that the CD in RT is required for tRNALys3
annealing, i.e. virions inwhich GagPol is C-terminally deleted through
the RT CD can still selectively package tRNALys3, but don't anneal it to
the viral RNA genome. This could mean that a Gag/LysRS/RT
interaction may be involved in conformation changes facilitating
movement of tRNALys3 towards the primer binding site on the viral
RNA. The annealing of tRNALys3 to viral RNA may not only involve Gag
NC and tRNALys3, but RT as well, and a Gag/LysRS/RT interaction may
bring a tRNALys3/RT complex to the primer binding site where, once




The plasmids used in this study are listed in Table 1. GagFS−
codes for all HIV-1 proteins except GagPol, and was constructed as
previously described (Liang et al., 1997). It contains mutations at the
GagPol frame shift site (2082-TTTTTT-2087 replaces 2082-CTTCCT-
2087) that prevent frameshifting. RSV.Gag.P−, previously named
pSV.Myr1.3 h, was a gift from R. Craven and J. Wills (University of
Pennsylvania, Philadelphia), and was constructed as previously
described (Craven et al., 1991). It encodes a myristylated RSV Gag
protein and the ﬁrst seven amino acids of RSV protease. Except for
Gag made from GagFS−, all HIV-1 proteins expressed in cells (Gag,
GagΔP6, Pol, RT, and corresponding truncated fragments), were
expressed from codon-optimized mRNAs. These proteins have
identical amino acid sequences to their viral counterparts, but the
mRNA coding for them have had their codons optimized for
mammalian cell codon usage, which results in more efﬁcient
translation and protein production and also makes nuclear export
of these mRNAs Rev-independent through modiﬁcation of the
multiple inhibitory sequences (Huang et al., 2001). The construction
of Gag plasmid was previously described (Huang et al., 2001). The
GagΔp6 plasmid was PCR-ampliﬁed from Gag plasmid and digested
116 J. Saadatmand et al. / Virology 380 (2008) 109–117with SalI and XbaI, whose sites were introduced in each of the
following primers: 5′-ATAATAGTCGACATGGGCGCCCGCGCCAGCGTG-
3′ (sense); 5′-GCGGCGTCTAGATTAAAAATTCCCTGGCCTTCC-3′ (anti-
sense). This PCR fragment was cloned into the SalI and XbaI sites of
pNGVL-3 plasmid backbone after the removal of hGag.
hPol cDNA was PCR-ampliﬁed from a plasmid coding for hPol (a
gift from Y. Huang and G. Nabel, Vaccine Research Center, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland (Huang et al., 2001)), and digested with
SalI and EcoRI, whose sites were introduced into each of the PCR
primers that also contained V5 sequences, as previously described
(Cen et al., 2004b). Pol cDNA (coding for the ﬁrst 1001 amino acids
of Pol) was then cloned into a plasmid pNGVL-3 (a gift from Y.
Huang and G. Nabel) from which GagPol had been removed, and Pol
fragments were ampliﬁed using speciﬁc PCR primers. Both Pol and
Pol fragments contain C-terminal V5 sequence, and an inactive
protease due to an R42G mutation in the active site in protease. Pol
fragments were constructed using Pol as a template and the coding
regions are indicated for each fragment as follows: PR-C (amino
acids 58–1001) a fragment that is missing P6⁎; FP-C fragment
(amino acids 155–1001) missing P6⁎ and protease; TH-C fragment
(amino acids 238–1001) missing P6⁎, Protease, and ﬁnger/palm
domains; CD-C (amino acids 476–1001) fragment missing P6⁎,
protease, and the ﬁnger/palm and thumb domains; N-RN (amino
acids 1–714), a fragment missing integrase. RT (amino acids 155–
714) was ampliﬁed from the N-RN fragment. Other RT fragments
were ampliﬁed from RT and the coding regions are indicated as
follows: PA-CD (amino acids 155–584); FP-TH (amino acids 155–
475); TH-CD (amino acids 397–584); CD-RN fragment (amino acids
476–714). All plasmids were veriﬁed by sequencing (McGill
University and Genome Quebec Innovation Centre, Montreal,
Quebec). Plasmid pLysRS contains cDNA encoding full-length (1 to
597 amino acids) human LysRS, as previously described (Javanbakht
et al., 2003), and expresses wild-type LysRS protein in transfected
293T cells.
Production of Gag viral-like particles (VLPs) and incorporation of
Pol or RT
HEK-293T cells were grown in complete Dulbecco's modiﬁed
Eagle's medium (DMEM) plus 10% fetal bovine serum (FBS), 100 U of
penicillin, and 100 μg of Streptomycin per ml, were transfected
using Lipofectamine 2000 (Invitrogen), according to the manufac-
turer's instructions. Cell culture supernatant was collected 48 h
post-transfection. Gag viral-like particles (VLPs) were pelleted from
culture medium by centrifugation in a Beckman SW41 rotor at
35,000 rpm for 1 h through a 20% sucrose cushion. The pellet of
puriﬁed Gag VLPs was resuspended in lysis buffer (RIPA buffer:
10 mM Tris, pH 7.4; 100 mM NaCl; 1% sodium deoxycholate; 0.1%
sodium dodecyl sulfate [SDS]; 1% NP-40; 2 mg of aprotinin/ml; 2 mg
of leupeptin/ml; 1 mg of pepstatin A/ml; 100 mg of phenylmethyl-
sulfonyl ﬂuoride/ml).
Coimmunoprecipitation of LysRS or Gag with Pol or RT
Transfected 293T cells, removed 48 h. post-transfection, were
washed with PBS, and lysed in 350 μl RIPA buffer. Insoluble material
was pelleted at 1800 ×g for 30 min in an IEC MICROCL 21
microcentrifuge, and the supernatant was used for coimmunopreci-
pitation studies. 20 μl anti-LysRS and 400 μl of 50% (w/v) protein A-
Sepharose (Pharmacia) were incubated together in 10 ml of 0.2 M
triethanolamine pH 9. Dimethyl pimelimidate (DMP) cross-linker
(Pierce) was then added to a ﬁnal concentration of 20 mM, and the
mixture was incubated overnight at 4 °C. The beads were thenwashed
three times with 10 ml of 0.2 M triethanolamine pH 9. Equal amounts
of protein in cell supernatant (approximately 200–500 μg, asdetermined by the BioRad assay) were incubated with 40 μl antibody
cross-linked to protein A-Sepharose overnight at 4 °C. The immuno-
precipitate was then washed three times with Net gelatin buffer
(50 mM Tris–HCl, pH 7.5, 150 mMNaCl, 0.1% NP-40, 1 mM EDTA, 0.25%
gelatin). After the ﬁnal supernatant was removed, 50 μl of 2× sample
buffer (120 mM Tris HCl, pH 6.8, 20% glycerol, 4% SDS, and 0.02%
bromphenol blue) was added and the precipitate was then boiled for
10 min to release the precipitated proteins. After microcentrifugation,
the resulting supernatant was analyzed using Western blots.
RNase A and T1
Cell lysates were immunoprecipitated as described above. The
immunoprecipitates were then treated with RNase A (Fermentas) and
T1 (Ambion) for 2 h at 37 °C in 50 μl RIPA buffer, washed three times
with Net gelatin buffer, resuspended in 2× loading dye, followed by
western blots as described below.
Protein analysis
Viral and cellular proteins were extracted with RIPA buffer,
resolved by SDS-PAGE (10% acrylamide), followed by blotting onto
nitrocellulose membranes (Amersham Pharmacia Biotech). Detection
of protein by Western blotting utilized monoclonal antibodies that
are speciﬁcally reactive with HIV-1 RT p66 (HIV-1 RT monoclonal
antibody (7E5), Cat. #7372, NIH AIDS Research and Reference
Reagent Program), a polyclonal antibody for human LysRS (Pocono
Rabbit Farm and Laboratory, Inc.), and monoclonal antibodies for V5
(Sigma), β-actin (Sigma), GAPDH (Santa Cruz), HIV-1 capsid (Zepto
Metrix), and RSV CA (a gift from Dr. Volker M. Vogt, Cornell
University). Detection of proteins was performed by enhanced
chemiluminescence (NEN Life Sciences Products) using the following
secondary antibodies obtained from Amersham Pharmacia Biotech:
anti-mouse (for HIV-1 CA, RT, V5, β-actin, and GAPDH) and anti-
rabbit (for LysRS, and RSV CA).
siRNA transfection
T3 siRNA to LysRS and control siRNA to luciferase were
constructed as previously described (Guo et al., 2003). At 24 h
before transfection, HEK-293T cells were trypsinized and plated in
six-well plates at 1.0×105 cells per well in 2 ml of DMEM
supplemented with 10% FBS. The cells were incubated at 37 °C in
a CO2 incubator until 60–80% conﬂuent. These HEK-293T cells were
transfected with siRNA, using cationic lipid complexes that were
prepared by incubating 50 pmol of indicated siRNA with 5 μl of
DMRIE-C reagent (Invitrogen) in 200 μl of DMEM for 20 min, and
were then added to the wells in a ﬁnal volume of 0.75 ml with
serum-free DMEM. Eight hours later, HEK-29T cells were cotrans-
fected with HIV-1 Gag or RT DNA using the Lipofectamine 2000
reagent (Invitrogen), following the protocol set by the manufacturer.
An additional 1.00 ml of DMEM containing 20% FCS was also added
to the cells at this time. Cells were then cultured and assayed for the
appropriate activity at 48 h post-transfection.
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